ShangPharma Opens cGMP Manufacturing Facility

ShangPharma announced the opening of a new cGMP manufacturing facility in the Shanghai suburb of Fengxian. The plant will allow ShangPharma to support its clients through Phase II and Phase III trials. Previously, the CRO/CMO was limited to providing clients with product for early discovery and then GLP Toxicology testing and a Phase I trial. More details.... Stock Symbol: (NYSE: SHP)